Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 27Recruiting 8Active not recruiting 7Terminated 4Not yet recruiting 3Withdrawn 1Unknown 1Approved for marketing 1

Sponsor Class

OTHER 13OTHER_GOV 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 1

Interventions

Injections 54Cisplatin 49Paclitaxel 48Carboplatin 43Gemcitabine 38pembrolizumab 36Docetaxel 36Capecitabine 36Drug Therapy 34anlotinib 25Bevacizumab 25Fluorouracil 24Cyclophosphamide 24icotinib 23Oxaliplatin 20fludarabine 19Pemetrexed 17Leucovorin 16Irinotecan 16Temozolomide 14Nivolumab 14Doxorubicin 14Cetuximab 14camrelizumab 13apatinib 13Trastuzumab 12Rituximab 11Fulvestrant 11Etoposide 11tesetaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × INDUSTRY × trifluridine tipiracil drug combination × Clear all
NCT06039202 2023-09-15

Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer

Holy Stone Healthcare Co., Ltd

Phase 2 Unknown
100 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡